Latest Information Update: 17 Jul 2002
At a glance
- Originator Fujisawa
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 23 Jun 1998 Commercial data reviewed by Fujisawa
- 08 Oct 1996 Preclinical development for Type-2 diabetes mellitus in Japan (Unknown route)